AUSTIN, Texas, July 12, 2012 /PRNewswire/ -- EPIC Corporation
(OTC: EPOR) (the "Company") a healthcare company announced that it
has received a commissioned market report regarding the healthcare
and medical niche market segments for its AcuFAB™ and
AcuPAD™ solutions. Click here to download a copy
of the report. EPIC is offering AcuFAB™ to OEMs
of healthcare, medical and consumer products, and is accepting
applications from qualified wholesale and retail distributors
to distribute AcuPAD™ products.
EPIC's business model is similar Intel's famous "Intel inside"
model. EPIC like Intel sells its technology,
AcuFAB™, directly to OEMs and produces AcuPAD™
products to sell to wholesale and retail distributors and
OEM's. However, unlike Intel which sells only business to
business, EPIC is able to sell its AcuPAD™ products directly to the
consumer.
The report only evaluates the mattress overly market relating to
the prevention of pressure sores, and does not discuss the market
for mattress overlays that provide a more comfortable and restful
nights sleep, chair pads, car and truck seat pads, compression
bandages, shoe inserts, and other products that can be made with
AcuFAB™.
The Market Report provides in-depth (segment) analysis and
market potential for mattress overlays relating to pressure sores.
The AcuPAD™ Mattress overlays also provide a more
comfortable, deep un-interrupted sleep. Chair cushions and
car and truck seating pads made from AcuFAB™
provide comfort and relief from lower back, shoulder and neck
pains.
Market Summary
The US Supreme Court's decision to uphold the Affordable Care
Act gives more significance to the report. The decision
means, like the report states, healthcare will " gravitate more and
more into preventative medicines and chronic therapeutic regiments
. . . because of large spikes in obesity, diabetes, and an ever
increasing sedentary life style, we are dealing with the increasing
need for handling wounds preemptively . . . . [I]t really will
always be about low blood circulation to surface tissue."
(Market Intelligence Report, June 25,
2012, "Market Summary")
EPIC's uniquely designed AcuFAB™ is an acupressure
specialty spacer fabric with concave and convex channels running
parallel to the acupressure meridians and pressure points in the
body.
EPIC's AcuPAD™ products, made with
AcuFAB™, "can optimize the way that
both the blood vessels and lymphatic system distributes fluids to
and from the surface tissue. By so doing, it is quite
possible that we can avoid pressure ulcers, diabetic ulcers, and
various other surface tissue lesions caused by a lack of oxygen to
these tissues . . . By facilitating blood flow and by extension
oxygen offload to surface tissues, not only can the inception of
these debilitating sores be prevented but also those that have
started to come about can be addressed early with combination of
antibiotics and circulation management." (ibid.)
Due to the current economic conditions "and incredible pressure
on the healthcare system . . . it would figure that one of the best
ways to handle this is to mitigate . . . bed stays. Not every
one can be helped by prudent [and effective] pressure overlay
methodology, but many patients definitely can be helped and the
amount of money that could be saved is staggering and is in the
billions." (ibid.)
Business Highlights
The following are the "Business Highlights" of the Market
Report:
- Unique product architecture and design superior to competitors
with proprietary processes and specific manufacturing processes
that are surrounded by intellectual property.
- Demographic tailwinds hugely positive for product selection and
placement as we have large problems with diabetes, obesity,
cardiovascular disease, and chronic neurological disease which will
bring about the need for attention to surface tissues.
- Uncertain environment has left a lack of commitment by larger
players as reimbursement and customer traction has curtailed large
investment in any area fraught with proof of concept or defined
patient parameters.
- Very low valuation of a start up organization with a product in
place and the capital to gather enough traction to take some share
of a large existing market.
- Market size unknowable as the patient population is growing
rapidly and the efficacy of such a solution in a large patient
population over many modalities is not known.
- The cause and effect argument of surface tissue lesions is very
straight forward as it is caused by a lack of blood circulation and
the company's products have been shown to have positive impact on
this. (ibid.)
Conclusion
The following is the "Conclusion" of the Market Report.
Epic Corporation has a proprietary and patent protected
manufacturing process for a fabric solution which offers great
advantages to the surface tissue in contact with it. In a
world where we have major problems with sedentary lifestyles, poor
eating habits, and healthcare issues, these solutions may be the
answer for patients everywhere. What is most intriguing is
that these products have some technological barriers to entry yet
do not have to go through the rigorous FDA approval process.
With some very reasonable hurdles, the company can get
reimbursement for its products as the economic problem is very real
and very large.
This company is a very good way to play a global trend when the
sentiment around such opportunities is at its lowest. The
most compelling thing about this opportunity is its very low
valuation, limited operational burn rate and its proprietary
processes. Further, the market overall is growing rapidly,
and the overall demographic trend is fully intact.
Finally, this company is a very good place to be if in fact the
trend of pressure alleviation catches on in a very real way and
transcends the existing products the company is currently involved
with. There may be a large segment for custom business in
several areas which have up until now not been looked at.
This is a call option for the company as there are many areas such
as gloves, footwear, hospital gowns, etc., where these products may
very well be applicable and this is where It really gets
interesting. (ibid.)
EPIC's mission is to provide people with better
healthcare. Visit www.epiccor.com for corporate
information and www.otcmarkets.com for investor information.
CONTACT:
Ronald Tucker CEO
Email: info@eporco.com
Telephone: (866) 737-1413
SOURCE EPIC Corporation
